Protara Therapeutics (TARA) Non-Current Deferred Tax Liability (2019 - 2023)

Protara Therapeutics (TARA) has 5 years of Non-Current Deferred Tax Liability data on file, last reported at $9.6 million in Q4 2023.

• On a quarterly basis, Non-Current Deferred Tax Liability rose 43786.36% year-over-year to $9.6 million in Q4 2023; TTM through Dec 2023 was $9.6 million, a 43786.36% increase from a year earlier, with the FY2023 full-year figure at $9.6 million, up 43786.36% from the prior year.
• Non-Current Deferred Tax Liability for Q4 2023 stood at $9.6 million, up from -$22000.0 in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for TARA reached as high as $9.6 million in Q4 2023 and fell as low as -$22000.0 in Q4 2022.
• Historically, Non-Current Deferred Tax Liability has averaged $1.6 million across 5 years, with a median of $355500.0 in 2020.
• Across the five-year window, Non-Current Deferred Tax Liability slumped 101.42% in 2022 and soared 43786.36% in 2023, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $2000.0 in 2019, then surged by 16000.0% to $322000.0 in 2020, then surged by 381.06% to $1.5 million in 2021, then slumped by 101.42% to -$22000.0 in 2022, then surged by 43786.36% to $9.6 million in 2023.
• Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $9.6 million in Q4 2023, -$22000.0 in Q4 2022, and $829000.0 in Q3 2022.